2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107622
    (E/Z)-BIX02188 1094614-84-2 98%
    (E/Z)-BIX02188 is a MEK5/ERK5 pathway inhibitor. (E/Z)-BIX02188 inhibits the catalytic function of purified MEK5 enzyme.(E/Z)-BIX02188 can be used for the role of MEK5/ERK5 pathway in various biological systems .
    (E/Z)-BIX02188
  • HY-107901
    Pparδ agonist 1 1902161-12-9 98%
    Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
    Pparδ agonist 1
  • HY-108040
    NCX-6560 803728-45-2 98%
    NCX-6560 is an orally active nitric oxide releasing derivative of atorvastatin that inhibits cholesterol biosynthesis and has anti-inflammatory and antithrombotic activity.
    NCX-6560
  • HY-108061
    A-348441 639520-46-0 98%
    A-348441 is a liver selective glucocorticoid receptor antagonist. A-348441 can reduce the glucose level in the liver. A-348441 can be used for the research of metabolic disease, such as type 2 diabetes.
    A-348441
  • HY-108248
    KU-32 956498-70-7 98%
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
    KU-32
  • HY-108303
    Neridronate sodium 80729-79-9 98%
    Neridronate sodium is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate sodium inhibits capillary tube formation. Neridronate sodium itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate sodium can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.
    Neridronate sodium
  • HY-108308
    Ibuprofen guaiacol ester 66332-77-2 98.49%
    Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is a potent and orally active prostaglandin synthesis inhibitor. Ibuprofen guaiacol ester has the potential for the research of edema and fever.
    Ibuprofen guaiacol ester
  • HY-108409
    Progesterone carboxylic acid 302-97-6 98%
    Progesterone carboxylic acid (Testosterone-17β-carboxylic acid) is an androstenedione analogue. Progesterone carboxylic acid can conjugate with 20-mer peptide nucleic acid (PNA) and the conjugate has superior binding capacity on complementary DNA. Progesterone carboxylic acid can be used for cancers and type 2 diabetes (T2D) research.
    Progesterone carboxylic acid
  • HY-108433
    CPT2 1670277-66-3 98%
    CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research.
    CPT2
  • HY-108524
    LG101506 331248-11-4 98%
    LG101506 is a selective and orally active RXR modulator with a Ki of 2.7 nM for RXRα. LG101506 can be used for the research of type 2 diabetes and cancer.
    LG101506
  • HY-108572
    S26948 353280-43-0 98%
    S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ.
    S26948
  • HY-108614
    GPi688 918902-32-6 98%
    GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively. GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia.
    GPi688
  • HY-108651
    Uridine-5'-O-3-thiotriphosphate trisodium 1266569-94-1 98%
    Uridine-5'-O-(3-thiotriphosphate) trisodium, a stable analogue of UTP, is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability.
    Uridine-5'-O-3-thiotriphosphate trisodium
  • HY-108663
    5-OMe-UDP 1207530-98-0 98%
    5-OMe-UDP (5-methoxyuridine 5'-trihydrogen diphosphate) is a P2Y6 receptor agonist (EC50=0.08 μM). 5-OMe-UDP activates the P2Y6 receptor by binding to it, which triggers signaling pathways within the cell. This activation can lead to an increase in intracellular calcium ion concentration, which in turn regulates cellular function. The methoxy groups of 5-OMe-UDP provide additional activity and selectivity, contributing to the binding of 5-OMe-UDP to the P2Y6 receptor. 5-OMe-UDP can be used to study diseases related to P2Y6 receptor function, such as diabetes, inflammatory bowel disease, Alzheimer's disease, etc.
    5-OMe-UDP
  • HY-108664
    MRS2957 1228271-30-4 98%
    MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.
    MRS2957
  • HY-108680
    Carbazeran citrate 153473-94-0 98%
    Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease.
    Carbazeran citrate
  • HY-108807
    Glucarpidase 1622456-55-6 98%
    Glucarpidase is an enzyme that inactivates methotrexate. Glucarpidase can be used for renal dysfunction diseases research.
    Glucarpidase
  • HY-108826
    Iduronate sulfatase 50936-59-9 98%
    Iduronate sulfatase (Iduronate sulfate sulfatase) is an exo-sulfatase that hydrolyzes the C2-sulfate ester bond from nonreducing terminal α-L-iduronic acid residues in HS.
    Iduronate sulfatase
  • HY-108830
    Galsulfase 552858-79-4 98%
    Galsulfase (Aryplase, BM-102) is recombinant human N-acetylgalactosamine-4-sulfatase. Galsulfase (Aryplase, BM-102) can be used for mucopolysaccharidosis (MPS) research.
    Galsulfase
  • HY-109130
    Fadaltran 1799809-36-1 98%
    Fadaltran (BAY 1193397) is an orally active α2C-adrenoreceptor antagonist. Fadaltran can be used for the study of diabetic foot ulcers.
    Fadaltran
Cat. No. Product Name / Synonyms Application Reactivity